Key Takeaways J&J's Innovative Medicine unit is expected to post Q1 growth despite Stelara LOE impactJNJ's growth likely driven by Darzalex, Tremfya, Erleada and the uptake of newer therapies like CarvyktiJNJ faces pressure from Stelara biosimilars, Imbruvica decline and Part D redesign headwindsJohnson & Johnson (JNJ) , via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, ...

Key Takeaways Merck (MRK) has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, particularly in oncology and immunology. The company's recent deals reflect a strategy to diversify its broader portfolio and secure next-generation therapies, while maintaining competitive leadership. Earlier this week, Merck announced a definitive agreement to acquire California-based cancer biotech, Terns Pharmaceuticals (TERN) , for $53.00 per share in cash, a tota ...

Key Takeaways Merck's (MRK) stock has risen 51.4% in the past six months. A key driver of the increase is Merck's improved outlook for long-term growth once its blockbuster drug, Keytruda, loses patent exclusivity. Keytruda, approved for several types of cancer, alone accounts for around 55% of the company's pharmaceutical sales. The drug has played an instrumental role in driving Merck's steady revenue growth over the past few years. However, there were rising concerns about the firm's ability to grow its ...

Key Takeaways Tempus AI expands 2026 footprint via collaborations across pharma, healthcare, and tech sectors. TEM partners with Daiichi Sankyo to advance oncology ADC program using PRISM2 AI models. Tempus AI integrates Median tech and teams up with NYU Langone to enhance diagnostics and cancer care. Tempus AI (TEM) continues to expand its footprint in 2026 through a series of strategic collaborations. By partnering with leading pharmaceutical companies, healthcare institutions, and technology innovators, ...

Key Takeaways Merck is looking to acquire Terns for $53 per share, valuing the deal at almost $6.7B equity.Terns TERN-701, a leukemia drug candidate, showed strong early clinical response rates in studies.Merck is ramping up merger and acquisition deals in recent times to offset Keytruda's 2028 patent loss.Merck (MRK) announced that it has entered into a definitive agreement to acquire California-based cancer biotech, Terns Pharmaceuticals (TERN) , for $53.00 per share in cash or an estimated equity value o ...

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks Investors Are Buying Now. Enliven Therapeutics soared to a new five-year high on Wednesday, as investors took heart from two analysts’ optimistic coverage for the stock, with one raising its price target by 9.7 percent. In intra-day trading, the stock climbed to a record high of $36.65 before paring gains to finish the session just up by 14.06 percent at $35.53 apiece. Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Le ...

The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.The Financial Times was the first to report the deal.Pipeline Pressure Mounts Ahead Of Keytruda ExpiryThe deal reflects Merck's broader strategy to replenish its pipeline ahead of Keytruda's expected patent expiry as early as 2028.Keytruda, a cancer immunotherapy, generates about $30 billion annually, making it central to the company's growth trajectory.Merck has been among the most aggressive acquirers in bio ...

Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders Accessibility StatementSkip NavigationMILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.Click hereto learn how to join our investigation and obtain additional information or contact us at [email protected]or toll-free: 866- ...

Merck & Co (NYSE:MRK) M&A announcement March 25, 2026 08:00 AM ET Company ParticipantsCaroline Litchfield - CFODean Li - President of Merck Research LaboratoriesEvan Seigerman - Managing Director and Head of Healthcare ResearchJannie Oosthuizen - EVP and President of Oncology and MSD InternationalJason Gerberry - Managing Director of Equity ResearchLuisa Hector - Head of Global Pharma Equity Research and Co-Head of the Global Pharmaceuticals TeamMarjorie Green - SVP and Head of Oncology, Global Clinical Dev ...

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a ...